<i>TERT</i> promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism

P. Sivaramakrishna Rachakonda, Md. Ismail Hosen, Petra J. de Verdier, Mahdi Fallah, Barbara Heidenreich, Charlotta Ryk, Peter Wiklund, Gunnar Steineck, Dirk Schadendorf, Kari Hemminki,

Proceedings of the National Academy of Sciences · 2013 · 335 citations · 25 references

DOIFull text

Open access

Concepts

TL;DR

TERT promoter mutations are a frequent telomerase‑activating alteration in several cancers, including bladder cancer. The study aimed to determine how often these mutations occur in bladder tumors and what clinical effects they have. Researchers examined 327 urothelial carcinoma specimens, identifying mutations at positions –124 and –146 bp that create Ets/TCF binding sites. The mutations were present in 65.4 % of tumors, and their adverse impact on survival and recurrence was mitigated by the rs2853669 polymorphism, which reduced mortality risk and recurrence in low‑stage disease.

Abstract

The telomerase reverse transcriptase (TERT) promoter, an important element of telomerase expression, has emerged as a target of cancer-specific mutations. Originally described in melanoma, the mutations in TERT promoter have been shown to be common in certain other tumor types that include glioblastoma, hepatocellular carcinoma, and bladder cancer. To fully define the occurrence and effect of the TERT promoter mutations, we investigated tumors from a well-characterized series of 327 patients with urothelial cell carcinoma of bladder. The somatic mutations, mainly at positions -124 and -146 bp from ATG start site that create binding motifs for E-twenty six/ternary complex factors (Ets/TCF), affected 65.4% of the tumors, with even distribution across different stages and grades. Our data showed that a common polymorphism rs2853669, within a preexisting Ets2 binding site in the TERT promoter, acts as a modifier of the effect of the mutations on survival and tumor recurrence. The patients with the mutations showed poor survival in the absence [hazard ratio (HR) 2.19, 95% confidence interval (CI) 1.02-4.70] but not in the presence (HR 0.42, 95% CI 0.18-1.01) of the variant allele of the polymorphism. The mutations in the absence of the variant allele were highly associated with the disease recurrence in patients with Tis, Ta, and T1 tumors (HR 1.85, 95% CI 1.11-3.08). The TERT promoter mutations are the most common somatic lesions in bladder cancer with clinical implications. The association of the mutations with patient survival and disease recurrence, subject to modification by a common polymorphism, can be a unique putative marker with individualized prognostic potential.

References

25